GC Biopharma녹십자
006280 · KOSPI · ₩006280 · 녹십자
₩132,000▲ ₩1,500 (1.15%)End-of-day · Oct 29, 2026 · End-of-day prices.
This company's bonds, credit rating and how its shares have moved with rates and the won.
Credit rating
- A+stable outlookNICE Investors Service · corporate bonds · Rated Jun 30, 2026
- A+stable outlookKorea Ratings · corporate bonds · Rated Jun 2, 2026
Bonds outstanding
₩286B in 3 bonds
- ≤6 months₩130B
- 6–12 months—
- 1–2 years₩60B
- 2–3 years₩96B
- 3–5 years—
- Over 5 years—
We read bond filings from Oct 25, 2021; older bonds may be missing.
Due soon vs cash
- Due in 6 months
- ₩130B
- Due in 12 months
- ₩130B
- Cash and equivalents
- ₩42B
Cash from the 2026 H1 statements
More bonds fall due in the next 6 months than the company holds in cash.
How it has moved with rates and the won
Average move of the shares on days the factor changed, over the last year. Describes the past, not a forecast.
- −0.86% per 10 bp rise in KTB 3ysome link · correlation -0.14 over 253 days
- −0.48% per 1% rise in USD/KRWweak link · correlation -0.10 over 253 days
Recent bond deals
- Mar 10, 2026₩156B3y
Who else is affected
Customers and suppliers
Penetrium BioscienceHugelLinked events
- MaturitiesOct 23, 202685GC Biopharma: ₩130bn of bonds due in the next 6 months vs ₩42bn cash₩130bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.GC Biopharma
Also known as: GC Biopharma / 녹십자 / 006280 / KRX:006280
Source: KRX statistical information